CO7111276A2 - Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met - Google Patents

Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met

Info

Publication number
CO7111276A2
CO7111276A2 CO14238774A CO14238774A CO7111276A2 CO 7111276 A2 CO7111276 A2 CO 7111276A2 CO 14238774 A CO14238774 A CO 14238774A CO 14238774 A CO14238774 A CO 14238774A CO 7111276 A2 CO7111276 A2 CO 7111276A2
Authority
CO
Colombia
Prior art keywords
disubstituted
pyridine
modulators
compounds
triaolo
Prior art date
Application number
CO14238774A
Other languages
English (en)
Inventor
Swaroop Kumar V S Vakkalanka
Dhanapalan Nagarathnam
Srikant Viswanadha
Meyyappan Muthuppalaniappan
Govindarajulu Babu
Prashant Kashinath Bhavar
Original Assignee
Rhizen Pharmaceuticals S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48093046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7111276(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhizen Pharmaceuticals S A filed Critical Rhizen Pharmaceuticals S A
Publication of CO7111276A2 publication Critical patent/CO7111276A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención proporciona compuestos útiles como 5 moduladores de la proteína cinasa C-met, métodos para prepararlos, composiciones farmacéuticas que los contienen y métodos de tratamiento, prevención y/o mejora de enfermedades o trastornos mediados por la cinasa C-met con ellos.
CO14238774A 2012-03-30 2014-10-28 Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met CO7111276A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1262CH2012 2012-03-30

Publications (1)

Publication Number Publication Date
CO7111276A2 true CO7111276A2 (es) 2014-11-10

Family

ID=48093046

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14238774A CO7111276A2 (es) 2012-03-30 2014-10-28 Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met

Country Status (21)

Country Link
US (3) US9815831B2 (es)
EP (1) EP2831073B1 (es)
JP (1) JP6192708B2 (es)
KR (2) KR102164317B1 (es)
CN (2) CN104321322A (es)
AP (1) AP3908A (es)
AU (1) AU2013239398B2 (es)
BR (1) BR112014024251A8 (es)
CA (1) CA2865719C (es)
CL (1) CL2014002604A1 (es)
CO (1) CO7111276A2 (es)
EA (1) EA026412B1 (es)
ES (1) ES2856848T3 (es)
HK (1) HK1204612A1 (es)
IL (1) IL234513B (es)
MX (1) MX359888B (es)
MY (1) MY169268A (es)
NZ (1) NZ629499A (es)
PH (1) PH12014502166B1 (es)
SG (1) SG11201406185WA (es)
WO (1) WO2013144737A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011145035A1 (en) * 2010-05-17 2011-11-24 Indian Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
CA2865719C (en) * 2012-03-30 2020-09-22 Rhizen Pharmaceuticals Sa Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
GB201321741D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
AU2015240465B2 (en) 2014-04-04 2020-02-27 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
CA3217238A1 (en) * 2015-07-20 2017-01-26 Genzyme Corporation Colony stimulating factor-1 receptor (csf-1r) inhibitors
CN107573340B (zh) * 2017-10-23 2020-11-24 江西科技师范大学 2-氨甲酰基-4-芳杂吡啶类化合物的制备及应用
GB201803892D0 (en) 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents
WO2021226261A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
EP4267573A1 (en) 2020-12-23 2023-11-01 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
EP4329757A1 (en) * 2021-04-29 2024-03-06 Amgen Inc. Heterocyclic compounds and methods of use
CN114031562A (zh) * 2021-10-31 2022-02-11 南京碳硅人工智能生物医药技术研究院有限公司 一种具有抗肿瘤的吡啶衍生物的工艺优化

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
CH671155A5 (es) 1986-08-18 1989-08-15 Clinical Technologies Ass
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ATE156158T1 (de) 1992-04-14 1997-08-15 Cornell Res Foundation Inc Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung
US5646176A (en) 1992-12-24 1997-07-08 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (en) 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
HUP9903014A3 (en) 1996-07-18 2000-08-28 Pfizer Phosphinate derivatives having matrix metalloprotease inhibitor effect and medicaments containing the same
US6153609A (en) 1996-08-23 2000-11-28 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2277100C (en) 1997-01-06 2005-11-22 Pfizer Inc. Cyclic sulfone derivatives
TR199901849T2 (xx) 1997-02-03 2000-02-21 Pfizer Products Inc. Arils�lfonilamino hidroksamik asit t�revleri.
CA2279863A1 (en) 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
NZ336836A (en) 1997-02-11 2001-02-23 Pfizer Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
GEP20033067B (en) 1999-02-22 2003-09-25 Bristol Myers Squibb Co C-21 Modified Epothilones
EP1644528A2 (en) 2003-06-19 2006-04-12 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, the Department of Health and Human Services, Variants of human taste receptor genes
DE602004012578T2 (de) 2003-08-15 2008-12-11 Vertex Pharmaceuticals Inc., Cambridge Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
US7169800B2 (en) 2003-09-24 2007-01-30 Vertex Pharmaceuticals Incorporated Imidazole compositions useful as inhibitors of protein kinases
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
AU2004293019B2 (en) 2003-11-19 2010-10-28 Array Biopharma Inc. Bicyclic inhibitors of MEK and methods of use thereof
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
WO2006014325A2 (en) 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
ATE463486T1 (de) 2004-08-26 2010-04-15 Pfizer Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
JP2008510792A (ja) 2004-08-26 2008-04-10 ファイザー・インク タンパク質チロシンキナーゼ阻害剤としてのアミノヘテロアリール化合物
CN101018780B (zh) 2004-08-26 2012-01-11 辉瑞大药厂 作为蛋白激酶抑制剂的吡唑取代的氨基杂芳基化合物
US7528138B2 (en) 2004-11-04 2009-05-05 Vertex Pharmaceuticals Incorporated Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
WO2006108059A1 (en) 2005-04-06 2006-10-12 Exelixis, Inc. C-met modulators and methods of use
US7470693B2 (en) 2005-04-21 2008-12-30 Bristol-Myers Squibb Company Oxalamide derivatives as kinase inhibitors
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
AU2006320580B2 (en) 2005-11-30 2011-06-23 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CN101479255B (zh) 2006-03-22 2013-05-01 沃泰克斯药物股份有限公司 用于治疗增殖性病症的c-MET蛋白激酶抑制剂
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
TW200813021A (en) 2006-07-10 2008-03-16 Merck & Co Inc Tyrosine kinase inhibitors
EP2066676A1 (en) 2006-09-18 2009-06-10 Vertex Pharmaceuticals, Inc. HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF
NZ576278A (en) * 2006-10-19 2011-12-22 Signal Pharm Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
PT2081937E (pt) 2006-10-23 2012-10-15 Sgx Pharmaceuticals Inc Moduladores de proteína-cinase de triazolo-piridazina
CN101578275A (zh) 2006-10-31 2009-11-11 先灵公司 苯胺基哌嗪衍生物及其使用方法
WO2008060866A1 (en) 2006-11-14 2008-05-22 Smithkline Beecham Corporation Novel compounds
WO2008078085A1 (en) 2006-12-22 2008-07-03 Astrazeneca Ab Method
WO2008088881A1 (en) 2007-01-19 2008-07-24 Xcovery, Inc. Kinase inhibitor compounds
CA2679602A1 (en) 2007-02-23 2008-08-28 Eisai R&D Management Co., Ltd. Pyridine or pyrimidine derivative having excellent cell growth inhibition effect and excellent anti-tumor effect on cell strain having amplification of hgfr gene
FR2915198B1 (fr) * 2007-04-18 2009-12-18 Sanofi Aventis Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
WO2009002806A1 (en) 2007-06-22 2008-12-31 Arqule, Inc. Pyrrolidinone, pyrrolidine-2, 5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
MX2010004876A (es) 2007-10-29 2010-07-28 Schering Corp Derivados de diamido tiazol como inhibidores de la proteina cinasa.
CA2703981A1 (en) 2007-10-29 2009-05-07 Schering Corporation Heterocyclic urea and thiourea derivatives and methods of use thereof
EP2212318B1 (en) 2007-10-29 2013-07-24 Merck Sharp & Dohme Corp. Thiazole derivatives as protein kinase inhibitors
WO2009058729A2 (en) 2007-10-29 2009-05-07 Schering Corporation Thiazole carboxamide derivatives and their to treat cancer
CN102014627B (zh) * 2008-04-30 2014-10-29 国家卫生研究院 作为极光激酶抑制剂的稠合双环嘧啶化合物
CN102127096A (zh) 2009-12-31 2011-07-20 和记黄埔医药（上海）有限公司 三氮唑并吡啶和三氮唑并吡嗪化合物及其组合物和应用
WO2011079804A1 (en) * 2009-12-31 2011-07-07 Hutchison Medipharma Limited Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
WO2011145035A1 (en) * 2010-05-17 2011-11-24 Indian Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
CA2865719C (en) * 2012-03-30 2020-09-22 Rhizen Pharmaceuticals Sa Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
US9887269B2 (en) * 2015-11-30 2018-02-06 Taiwan Semiconductor Manufacturing Company, Ltd. Multi-gate device and method of fabrication thereof

Also Published As

Publication number Publication date
AU2013239398B2 (en) 2017-09-07
AU2013239398A1 (en) 2014-09-18
JP2015511629A (ja) 2015-04-20
ES2856848T3 (es) 2021-09-28
CA2865719C (en) 2020-09-22
MX2014011750A (es) 2015-10-22
US9815831B2 (en) 2017-11-14
US11066402B2 (en) 2021-07-20
EP2831073B1 (en) 2020-12-09
BR112014024251A8 (pt) 2018-01-23
MX359888B (es) 2018-10-15
SG11201406185WA (en) 2014-11-27
CA2865719A1 (en) 2013-10-03
CN104321322A (zh) 2015-01-28
US20150057309A1 (en) 2015-02-26
KR20200013111A (ko) 2020-02-05
WO2013144737A3 (en) 2013-12-05
EA026412B1 (ru) 2017-04-28
US20180072721A1 (en) 2018-03-15
HK1204612A1 (en) 2015-11-27
EA201491520A1 (ru) 2015-03-31
MY169268A (en) 2019-03-20
PH12014502166A1 (en) 2014-12-10
NZ629499A (en) 2016-05-27
KR102164317B1 (ko) 2020-10-13
IL234513B (en) 2019-08-29
AP2014007966A0 (en) 2014-09-30
CN107082779A (zh) 2017-08-22
KR20140144726A (ko) 2014-12-19
WO2013144737A2 (en) 2013-10-03
US20210371416A1 (en) 2021-12-02
AP3908A (en) 2016-11-24
JP6192708B2 (ja) 2017-09-06
CL2014002604A1 (es) 2015-04-10
EP2831073A2 (en) 2015-02-04
PH12014502166B1 (en) 2014-12-10

Similar Documents

Publication Publication Date Title
CO7111276A2 (es) Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met
CY1121170T1 (el) Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων
CO6551721A2 (es) Moduladores de cinasa novedosos
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
EA202090371A1 (ru) 1H-ПИРРОЛО[2,3-c]ПИРИДИН-7(6H)-ОНЫ И ПИРАЗОЛО[3,4-c]ПИРИДИН-7(6H)-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛКОВ BET
CU20130115A7 (es) Compuestos y composiciones como inhibidores de trk
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
UY35427A (es) Compuestos y sus usos en la modulación de la hemoglobina
CO7170166A2 (es) Inhibidores de pi3k delta selectivos
EA201291098A1 (ru) Новые соединения 3,5-дизамещенного-3h-имидазо[4,5-b]пиридина и 3,5-дизамещенного -3h-[1,2,3]триазоло[4,5-b]пиридина как модуляторы протеинкиназ
UY35425A (es) Compuestos y sus usos en la modulación de la hemoglobina
UY35426A (es) Compuestos y sus usos en la modulación de la hemoglobina
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
BR112017010311A2 (pt) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
CL2012002035A1 (es) Compuestos derivados de 1,2,6,7,8,9-hexahidrofuro[3,4-c]uinolina, inhibidores de cetp; procedimiento de preparacion de los compuestos principales intermediarios y de la composicion farmaceutica; composicion farmaceutica; sales farmaceuticas; utiles en el tratamiwento de tratornos cardipvasculares, tales como hipolipoproteinemia, dislipidemia, entre otras.
WO2014035846A3 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
CO2018005354A2 (es) Derivados novedosos de diamino piridina
BR112016004904A8 (pt) moduladores de receptor x do fígado (lxr), composição farmacêutica, seus usos e método para modular atividade de lxr
CL2016001024A1 (es) Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades.
BR112017011335A2 (pt) compostos de 4h-pirido[1,2-a]pirimidin-4-ona
EA202092370A1 (ru) Новые модуляторы киназ
EA201690655A1 (ru) Новые соединения в качестве модуляторов протеинкиназ